Is interleukin-4delta3 splice variant expression in bovine tuberculosis a marker of protective immunity?
Splice variants of the interleukin-4 (IL-4) cytokine gene have been described for humans, mice, and cattle. IL-4 splice variants have been shown to inhibit IL-4-mediated cellular responses and thus act as IL-4 antagonists. Recent work has highlighted the possibility of a correlation between IL-4 splice variants and protection against clinical tuberculosis. In this study we investigated the potential role of IL-4 splice variants IL-4delta2 and IL-4delta3 in cattle with bovine tuberculosis, using quantitative real-time reverse transcription-PCR. For this analysis we used naturally exposed tuberculin skin test-positive field reactor cattle, uninfected control cattle, and cattle from two experimental models of protective immunity against Mycobacterium bovis: (i) vaccination with M. bovis BCG and challenge with virulent M. bovis and (ii) infection with M. bovis and treatment with isoniazid (INH) prior to rechallenge. The cytokine levels of field reactor cattle were compared to the levels of uninfected controls, while in kinetic studies of BCG vaccination and INH treatment we compared pre-experimental values with sequential samples for each individual animal. The data revealed a significant increase in IL-4delta3 mRNA expression in field reactor cattle, which had no visible pathology compared to cattle with gross pathology typical of bovine tuberculosis. Increased IL-4delta3 expression in both cattle models of protective immunity (BCG vaccination and INH treatment) was transient over time, reaching significance in the INH treatment model. Our results support the hypothesis that IL-4delta3 is involved in protective immunity against M. bovis infection in cattle and are in accordance with clinical studies that have suggested a role for IL-4 splice variants in protective immunity in tuberculosis.
Rhodes
Shelley G
SG
Veterinary Laboratories Agency, Surrey KT15 3NB, United Kingdom. s.rhodes@vla.defra.gsi.gov.uk
Sawyer
Jason
J
Whelan
Adam O
AO
Dean
Gillian S
GS
Coad
Michael
M
Ewer
Katie J
KJ
Waldvogel
Andreas S
AS
Zakher
Anthony
A
Clifford
Derek J
DJ
Hewinson
R Glyn
RG
Vordermeier
H Martin
HM
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D015415:Biomarkers / Q000378:metabolism; D002417:Cattle; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D015847:Interleukin-4 / Q000378:metabolism*; D009163:Mycobacterium bovis / Q000276:immunology* / Q000472:pathogenicity*; D014374:Tuberculin Test; D032581:Tuberculosis Vaccines / Q000008:administration & dosage*; D014380:Tuberculosis, Bovine / Q000276:immunology* / Q000517:prevention & control
D001500:BCG Vaccine; D015415:Biomarkers; D016207:Cytokines; D032581:Tuberculosis Vaccines; C421402:interleukin-4 variant; D015847:Interleukin-4